Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Biotech's wellspring—a survey of the health of the private sector in 2014

Private biotech never had it so good. Although the number of startups formed did not increase dramatically, the sector grew in size and received much more money than in 2013.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Amount of VC funds raised and number of financings.
Figure 2: VC investment for biotech innovative companies by region.
Figure 3: A rounds per year.
Figure 4: Asset class returns by vintage year.
Figure 5: Startup formation.
Figure 6: Patents issued per year.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huggett, B. Biotech's wellspring—a survey of the health of the private sector in 2014. Nat Biotechnol 33, 470–477 (2015). https://doi.org/10.1038/nbt.3218

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3218

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research